The oncology landscape presents a strange paradox: the number of available investigator sites has surged by nearly 50% in five years, yet performance has remained flat. Up to 85% of trials still fail to meet their enrollment timelines. Why?
The answer lies in a broken strategy. Too many sponsors rely on the “usual suspects”, large, well-known academic centers. But these sites are often oversaturated with competing trials, leading to slow enrollment despite their prestigious reputations. For emerging biotech companies with limited historical data, it’s a challenge to see beyond these obvious but often inefficient choices.
This problem is compounded by the “precision medicine paradox.” Your therapy’s innovative, targeted nature dramatically shrinks the eligible patient pool, meaning every single site you select must be a high performer. There is no room for error.
Success in this environment requires a fundamental shift: from subjective feasibility to a predictive, data-driven system for site selection and management. It requires a methodology that can analyze global data to uncover the hidden gems, the high-performing sites your competitors are overlooking, and a process to activate them with speed and precision.
It requires a new playbook. We’ve written it.
Download our new White Paper,
“From Selection to Success”, for the complete framework.